Healthcare / Medical DevicesUpdated 2026-05-10 22:07 UTC

AIM/CREO stock hub

AIM/CREO has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AIM/CREOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

50.8M

London Stock Exchange AIM

Market data

Live price

Current market quote for this ticker.

Current price

AIM/CREO

In the news

Latest news · AIM/CREO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.9P50 16.9P75 23.5

Trailing P/E57.3

P25 15.9P50 22.9P75 35.8

ROE4.8

P25 -54.2P50 2.1P75 13.7

ROIC-51.6

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AIM/CREO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

182

Groups with data

Currency

GBP

Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United Kingdom
Country code	UK
Employees	129
Employees Change	-158%
Employees Change Percent	-55.05
Enterprise value	GBX 34.5M
Exchange	London Stock Exchange AIM
Financial currency	GBP
First seen	2026-05-10
Industry	Medical Devices
Isin	GB00BZ1BLL44
Last refreshed	2026-05-10
Market cap	GBX 50.8M
Price	GBX 12.55
Price currency	GBX
Rev Per Employee	35,658.91x
Sector	Healthcare
Sic	3845
Symbol	aim/CREO
Website	https://www.creomedical.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	0.98%
EV Earnings	69.02x
EV/FCF	4.93x
EV/Sales	7.5x
FCF yield	13.78%
P/B ratio	0.83x
P/E ratio	57.26x
P/S ratio	11.05x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
FCF margin	152.17%
Gross margin	45.65%
Gross Profit	GBX 2.1M
Gross Profit Growth	10.53%
Gross Profit Growth Q	25%
Gross Profit Growth3 Y	-47.78%
Gross Profit Growth5 Y	-30.09%
Net Income	GBX 500,000
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	41.3%
Profit Margin	10.87%
Profit Per Employee	GBX 3,876
ROA	-20.82
Roa5y	-20.73
ROCE	-36.62
ROE	4.8
Roe5y	-41.16
ROIC	-51.57

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	20.98%
Cagr3y	-20.25%
Cagr5y	-42.51%
EPS Growth Quarters	5
EPS Growth Years	0
Revenue Growth Q	37.5x
Revenue Growth Years	0x
Revenue Growth3 Y	-46.51x
Revenue Growth5 Y	-29.56x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	GBX 0.07
Assets	GBX 68.8M
Cash	GBX 20.5M
Current Assets	GBX 31.7M
Current Liabilities	GBX 6M
Debt	GBX 4.2M
Debt Equity	GBX 0.07
Debt FCF	GBX 0.6
Equity	GBX 60.9M
Interest Coverage	-57.5
Liabilities	GBX 7.9M
Long Term Assets	GBX 37.1M
Long Term Liabilities	GBX 1.9M
Net Cash	GBX 16.3M
Net Cash By Market Cap	GBX 32.08
Net Debt Equity	GBX -0.27
Net Debt FCF	GBX -2.33
Tangible Book Value	GBX 60.2M
Tangible Book Value Per Share	GBX 0.15
WACC	9.1

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.28
Inventory Turnover	0.43
Net Working Capital	GBX 7.5M
Quick ratio	4.47
Working Capital	GBX 25.7M
Working Capital Turnover	GBX 0.19

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-17.86%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	20.96%
200-day SMA	12.37
3Y total return	-49.29%
50-day SMA	12.72
50-day SMA vs 200-day SMA	50over200
5Y total return	-93.72%
All Time High	250
All Time High Change	-94.98%
All Time High Date	2018-10-02
All Time Low	9.22
All Time Low Change	36.1%
All Time Low Date	2025-04-23
ATR	0.91
Beta	0.9
Beta1y	1.37
Beta2y	0.87
Ch YTD	26.77
High	13
High52	18.5
High52 Date	2026-02-05
High52ch	-32.16%
Low	12.25
Low52	9.52
Low52 Date	2025-12-04
Low52ch	31.83%
Ma50ch	-1.32%
Price vs 200-day SMA	1.48%
RSI	51.76
RSI Monthly	38.28
RSI Weekly	48.96
Sharpe ratio	0.57x
Sortino ratio	1.11
Total Return	-17.86%
Tr YTD	26.77
Tr1m	15.4%
Tr1w	-0.59%
Tr3m	-29.3%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	GBX -23M
Operating margin	-500

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	364,199,093%
Net Borrowing	-900,000
Shares Insiders	3.58%
Shares Institutions	86.8%
Shares Out	402,473,319
Shares Yo Y	17.86%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	GBX 5.6M
Average Volume	731,488.45x
Bv Per Share	0.15
CAPEX	GBX 200,000
Ch1m	15.4
Ch1w	-0.59
Ch1y	20.96
Ch3m	-29.3
Ch3y	-49.29
Ch5y	-93.73
Ch6m	11.56
Change	-1.57%
Change From Open	0.4
Close	12.75
Days Gap	-1.96
Depreciation Amortization	-300,000
Dollar Volume	1,627,333.4
Earnings Date	2026-05-13
EBIT	GBX -23M
EBITDA	GBX -23.3M
EPS	GBX -0
F Score	5
FCF	GBX 7M
FCF EV Yield	20.28x
FCF Per Share	GBX 0.02
Financing CF	10,100,000
Fiscal Year End	December
Founded	2,003
Income Tax	GBX -700,000
Investing CF	-2,800,000
Is Primary Listing	1
Last Earnings Date	2025-12-23
Last Report Date	2025-06-30
Ma150	12.18
Ma150ch	3.01%
Ma20	12.4
Ma20ch	1.22%
Net CF	10,700,000
Next Earnings Date	2026-05-13
Open	12.5
P FCF Ratio	7.26
P OCF Ratio	7.47
Position In Range	40
Ppne	3,600,000
Price Date	2026-05-08
Ptbv Ratio	0.84
Relative Volume	0.18x
Revenue	4,600,000x
SBC By Revenue	30.43x
Share Based Comp	1,400,000
Tax By Revenue	-15.22x
Tr6m	11.56%
Volume	129,668
Z Score	1.76

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AIM/CREO pay a dividend?

Capital-return profile for this ticker.

Performance

AIM/CREO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AIM/CREO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+86.8%

Share of float held by funds and institutions

Insider ownership

+3.6%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+17.9%

Negative means the company is buying back shares.

Technical

AIM/CREO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

51.8

Neutral momentum band

Price vs 200-day MA

+1.5%

50/200-day relationship not available

Beta (5Y)

0.90

Moves roughly with the market

Sharpe ratio

0.57

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AIM/CREO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current aim/CREO stock rating?

aim/CREO is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full aim/CREO analysis?

The full report lives at /stocks/aim/CREO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for aim/CREO?

The latest report frames aim/CREO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the aim/CREO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.